Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Jie Mei, Shaohua Li, QiJiong Li, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 167-176
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Jiayi Wu, Zhenyu Yin, Yannan Bai, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1233-1240
Open Access | Times Cited: 105
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
Abdul Rehman Khan, Xuyong Wei, Xiao Xu
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1089-1115
Open Access | Times Cited: 77
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 26
Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
Xuqi Sun, Jie Mei, Wen‐Ping Lin, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 54
Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
Jiarui Li, Shihai Xuan, Peng Dong, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis
Shun-An Zhou, Qing-Mei Zhou, Lei Wu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 8, pp. 3672-3686
Open Access | Times Cited: 8
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Renguo Guan, Jie Mei, Wen‐Ping Lin, et al.
Hepatology International (2023) Vol. 17, Iss. 5, pp. 1279-1288
Closed Access | Times Cited: 16
Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis
Yang Yang Li, Wendao Liu, Junwei Chen, et al.
Cancer Medicine (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis
Yangyang Li, Jiandong Guo, Wendao Liu, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1286-1298
Open Access | Times Cited: 5
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
Long-Wang Lin, Kun Ke, Leye Yan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study
Min Deng, Hao Cai, Benyi He, et al.
International Journal of Surgery (2023)
Open Access | Times Cited: 11
Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers
Kanglian Zheng, Xiaodong Wang
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma
Min Deng, Rongce Zhao, Hao Zou, et al.
British Journal of Cancer (2025)
Closed Access
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review
Ying Wu, Zhimin Zeng, Shuanggang Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma
Baokun Liu, Lujun Shen, Wen Liu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1557-1567
Open Access | Times Cited: 3
Future perspectives on immunotherapy for hepatocellular carcinoma
Landon L. Chan, Stephen L. Chan
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review
Xing Lv, Pengbo Zhang, Erlei Zhang, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
Yalikun Kugeluke, Zhongchao Li, Jianxin Zhang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy
Xiaoping Yi, Yan Fu, Qianyan Long, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan
Juei-Seng Wu, Tzu‐Chun Hong, Hung‐Tsung Wu, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 2, pp. 849-862
Open Access | Times Cited: 8
Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study
Min Deng, Qiucheng Lei, Jiamin Wang, et al.
International Journal of Surgery (2023) Vol. 109, Iss. 5, pp. 1299-1310
Open Access | Times Cited: 8
Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
Yu-Jie Xu, ZhiCheng Lai, Minke He, et al.
Technology in Cancer Research & Treatment (2021) Vol. 20
Open Access | Times Cited: 18
Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma
Yongkang Xu, Shumin Fu, Mao Ye, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 14
Cancer Immunotherapy and Medical Imaging Research Trends from 2003 to 2023: A Bibliometric Analysis
Shuli Tang, Tiantian Fan, Xinxin Wang, et al.
Journal of Multidisciplinary Healthcare (2024) Vol. Volume 17, pp. 2105-2120
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top